Tumor-Absorbed Dose Predicts Progression-Free Survival Following 131I-Tositumomab Radioimmunotherapy

Tumor-Absorbed Dose Predicts Progression-Free Survival Following 131I-Tositumomab Radioimmunotherapy

The study aimed at identifying patient-specific dosimetric and nondosimetric factors predicting outcome of non-Hodgkin lymphoma patients after 131 I-tositumomab radioimmunotherapy for potential use in treatment planning.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of nuclear medicine (1978) 2014-05, Vol.55 (7), p.1047-1053
Hauptverfasser: Dewaraja, Yuni K., Schipper, Matthew J., Shen, Jincheng, Smith, Lauren B., Murgic, Jure, Savas, Hatice, Youssef, Ehab, Regan, Denise, Wilderman, Scott J., Roberson, Peter L., Kaminski, Mark S., Avram, Anca M.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The study aimed at identifying patient-specific dosimetric and nondosimetric factors predicting outcome of non-Hodgkin lymphoma patients after 131 I-tositumomab radioimmunotherapy for potential use in treatment planning.
ISSN:0161-5505
1535-5667
DOI:10.2967/jnumed.113.136044